TETRANITE WILL GO TO MARKET WITH ROBUST PATENT PROTECTION
RevBio has a robust and growing patent portfolio that will provide protection up to and through 2042. These patent families include coverage of RevBio’s product pipeline, such as compositions (including the TETRANITE bone adhesive and derivatives thereof), methods of use, ancillary devices, and packaging. RevBio also has an exclusive, worldwide license to patents from Stryker that cover additional adhesive compositions and methods of use. The entire patent portfolio covers a range of clinical uses including dental, cranial, spinal, and orthopaedics in both humans and animals. This patent portfolio will provide expansive worldwide coverage for the RevBio technology.
PATENTS
Granted: US8034034*, US11638777, US11247941, US10286102*, US9265857*, US8273803*, US8232327*, US9848867*, US8765189, US11759546, EP3957340A1, EP3496729A4, EP3402443A4, EP2911190T3*, EP2365994B1*, EP336795A4, EP4021844A4, EP2569342B1*, CA2987619A1, CA3048850A1*, CA2798710C*, CN108025107A, CN109219421A, IT202200026510T2*, DK2569342T3*, DK2365994T3*, DE602011072450T2*, DE602009043610T2*, AU2011250934B2*, AU2020340421, TWI501793B*, KR101769805B1*, ES2616857T3*, US12178937
Published: US2023/0211044A1, US20230329755, US2024/0180625, EP4252681A3, EP405458A4, EP4164522A4, EP4312805A1, CA3186906A1m, AU2022268291A1, AU2021293892A1, HK40010229A, HK1260777A, HK1253822A, HK1260548A, HK1261014A, WO2022204294A1, WO2023114440A3, WO2024026121A, WO2024/026121
*Exclusively licensed to RevBio